-
Press Release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
-
Press Release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
-
Press Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Press Release
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
-
Press Release
Novartis announces plans to build flagship manufacturing hub in North Carolina
-
Press Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Press Release
Novartis completes acquisition of Tourmaline Bio
-
Press Release
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
-
Press Release
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
-
Press Release
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
-
Press Release
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
-
Press Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population